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Amyotrophic lateral sclerosis (ALS) is a progressive fatal multisystemic
neurodegenerative disorder caused by preferential degeneration of upper and
lower motor neurons. To further delineate the genetic architecture of the disease, we
used comprehensive panel sequencing in a cohort of 80 German ALS patients. The
panel covered 39 confirmed ALS genes and candidate genes, as well as 238 genes
associated with other entities of the neurodegenerative disease spectrum. In addition,
we performed repeat length analysis for C9orf72. Our aim was to (1) identify potentially
disease-causing variants, to (2) assess a proposed model of polygenic inheritance
in ALS and to (3) connect ALS with other neurodegenerative entities. We identified
79 rare potentially pathogenic variants in 27 ALS associated genes in familial and
sporadic cases. Five patients had pathogenic C9orf72 repeat expansions, a further four
patients harbored intermediate length repeat expansions. Our findings demonstrate
that a genetic background of the disease can actually be found in a large proportion
of seemingly sporadic cases and that it is not limited to putative most frequently
affected genes such as C9orf72 or SOD1. Assessing the polygenic nature of ALS, we
identified 15 patients carrying at least two rare potentially pathogenic variants in ALS
associated genes including pathogenic or intermediate C9orf72 repeat expansions.
Multiple variants might influence severity or duration of disease or could account
for intrafamilial phenotypic variability or reduced penetrance. However, we could not
observe a correlation with age of onset in this study. We further detected potentially
pathogenic variants in other neurodegeneration associated genes in 12 patients,
supporting the hypothesis of common pathways in neurodegenerative diseases and
linking ALS to other entities of the neurodegenerative spectrum. Most interestingly we
found variants in GBE1 and SPG7 which might represent differential diagnoses. Based
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on our findings, we recommend two-staged genetic testing for ALS in Germany in
patients with familial and sporadic ALS, comprising C9orf72 repeat analysis followed
by comprehensive panel sequencing including differential diagnoses that impair motor
neuron function to meet the complexity of ALS genetics.
Keywords: amyotrophic lateral sclerosis, neurodegeneration, next generation sequencing, genetic heterogeneity,
polygenic inheritance
INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating
multisystemic neurodegenerative disorder characterized by
degeneration of upper and lower motor neurons in the motor
cortex, brain stem, and spinal cord (Peters et al., 2015). ALS can
be inherited in an autosomal dominant, autosomal recessive
or X-linked manner. About 10% of cases are considered as
being familial (fALS), whereas the remaining 90% seem to occur
sporadically (sALS) with no family history of ALS. Since the first
discovery of SOD1 mutations being causative for ALS1 in 1993
(Rosen et al., 1993), researchers all over the world have made
great effort to further delineate the genetic basis underlying ALS.
Today, more than 30 confirmed major disease genes are listed
by the Amyotrophic Lateral Sclerosis Online genetics Database
(ALSoD1), the most frequently affected being C9orf72 (40% fALS,
5–6% sALS; pathogenic repeat expansion in the non-coding
region between exons 1a and 1b, detection by repeat analysis),
SOD1 (20% fALS, 3% sALS), FUS (5% fALS, <1% sALS) and
TARDBP (3% fALS, 2% sALS) (Abel et al., 2012; Su et al., 2014).
Screening of the known ALS genes identifies pathogenic
mutations in more than 60% of fALS cases. However, the same
genes that can be affected in fALS can also be found mutated in
sporadic cases, e.g., due to incomplete penetrance, false paternity,
recessive inheritance or de novo mutations (Su et al., 2014).
Mutations in disease genes affect different molecular pathways
which promote motor neuron degeneration and include
protein misfolding and subsequent aggregation, mitochondrial
dysfunction and oxidative stress, impaired RNA processing,
glutamate excitotoxicity and impaired axonal transport (Redler
and Dokholyan, 2012; Shaw, 2005). These findings provided
fundamental insight into basic underlying pathomechanisms
and additionally linked ALS to other disease entities like
frontotemporal dementia (FTD) or hereditary spastic paraplegia
(HSP).
With the application of genome-wide association studies
(GWASs) and high throughput sequencing technologies (next
generation sequencing, NGS), a large number of additional
disease genes, disease modifiers, and risk factors have been
identified especially in sALS. GWASs suggest that genetic
factors might contribute to a minimum of 23% of disease
risk, whereupon such factors do not necessarily have to be
directly causative but instead may act as risk factors or
disease modifiers (e.g., age of onset, disease progression) in
the interplay with environmental and stochastic factors (Renton
et al., 2014; Marangi and Traynor, 2015). Numerous GWASs
1http://alsod.iop.kcl.ac.uk/home.aspx
have been published which showed associations of various
loci with ALS containing potential risk genes such as FGGY,
ITPR2 and UNC13A (Marangi and Traynor, 2015) but until
now, causative variants in most of these genes have not been
identified. As GWASs are based on the “common disease –
common variant” hypothesis and odds ratios associated with
risk alleles are usually low, they are solely suitable for the
identification of common disease modifiers with low effect
size in complex disorders rather than rare causative variants
with large effect sizes. By contrast, NGS represents a powerful,
groundbreaking approach to detect rare variants with moderate
or high penetrance in Mendelian diseases without having
access to large pedigrees (He et al., 2014). ALS and other
neurodegenerative diseases which are characterized by great
genetic heterogeneity and sometimes overlapping symptoms
or even atypical phenotypes benefit to a great extent from
NGS and the possibility to analyze all genes implicated in the
disease in one approach. During the last years, the use of
NGS encompassed and considerably increased the number of
identified disease genes and risk factors for ALS, generating
further insight into underlying pathomechanisms at the same
time. One example is the recent discovery of the mitochondrial
protein CHCHD10 as being implicated in ALS which for
the first time proves a direct impact of mitochondria in
the pathogenesis of the disease, a result obtained by exome
sequencing in several families affected by ALS (e.g., Bannwarth
et al., 2014; Müller et al., 2014; Kurzwelly et al., 2015). As
sequencing costs and turnaround times substantially decreased
during the last years, the broad application of NGS has
triggered a fundamental shift not only in clinical genetics
but also in research on rare heritable diseases. Additionally,
by the analysis of large numbers of genes in parallel, it has
become evident that some patients carry potentially pathogenic
variants in genes that are associated with other entities of
the neurodegenerative spectrum. Besides this, one emerging
theme in ALS genetics is the presumption that ALS might
be a complex disease. This view arises mainly from the
observation of reduced penetrance in pedigrees affected by
fALS and the partially missing heritability in sporadic cases
(van Blitterswijk et al., 2012; He et al., 2014). In recent
studies, the authors applied NGS to identify patients who
carried pathogenic or potentially pathogenic variants in more
than one disease gene with frequencies ranging from 1.6% to
31.7% in fALS and sALS cohorts (van Blitterswijk et al., 2012;
Kenna et al., 2013; Cady et al., 2015). However, these studies
additionally point out that the genetic basis underlying ALS
in cohorts of different European countries and the US differs
due to founder effects and thus should not be assumed to be
homogeneous.
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Here we hypothesize that ALS is caused by polygenic
contributions from many disease-causing or disease-modifying
gene variants which encompass not only known ALS genes
but also other genes from the neurodegenerative disease
spectrum. To investigate this hypothesis, we used a high-
coverage targeted high-throughput sequencing approach to
detect variants in 39 ALS associated genes as well as 238
additional genes that are linked to other neurodegenerative
diseases in a German cohort of 80 clinically well characterized
ALS patients. We aim at identifying known causative
mutations and novel variants, to report on patients who
carry multiple potentially disease causing variants or variants
in genes which are implicated not only in ALS, but also
in other neurodegenerative disorders. To our knowledge,
this is the first report on extensive genetic screening in a
German ALS cohort including not only confirmed ALS
genes but also possible candidate genes, modifiers and risk
factors to assess the great genetic heterogeneity of ALS in
Germany.
MATERIALS AND METHODS
Study Participants
Our cohort includes 80 unrelated clinically diagnosed ALS
patients (55% male, 45% female; 7.5% familial, 92.5% sporadic;
82.5% ALS, 6.25% ALS-FTD, 2.5% flail leg, 2.5% flail arm,
6.25% primary lateral sclerosis (PLS)). Mean age of disease
onset was 60.1 years (range 29–88 years). Patients were recruited
consecutively in ALS outpatient clinics at the university
hospitals Rostock and Bochum (Germany). Relationship
was excluded by evaluation of family history. Only one
affected individual per family was included in this study and
there was no evidence of relationship between any study
participants. Informed written consent was obtained from all
participants. The study was approved by the local medical
ethics committee of Rostock University (A2009-10 and A2011-
56) and conducted in accordance with the Declaration of
Helsinki.
DNA Extraction
Genomic DNA was extracted from EDTA blood using the
QIAamp DNA Blood Mini Kit (Qiagen, Hilden, Germany)
according to the manufacturer’s protocol.
C9orf72 Repeat Analysis
All subjects were screened for a pathological repeat expansion
in the C9orf72 gene (GenBank NM_018325.3, NM_145005.5)
using fragment length analysis of fluorescence labeled PCR
products as repeat expansions cannot be detected by NGS
(method according to DeJesus-Hernandez et al., 2011). Based
on a repeat primed PCR we determined the size of GGGGCC
repeats (method according to Renton et al., 2011). Repeat
lengths of ≥ 30 units were considered as being pathogenic,
whereas repeat lengths of 20 to 29 units are considered as
intermediate.
Targeted Resequencing
Genomic DNA was enriched using a custom design Agilent
SureSelect in solution kit. The design of our diagnostic panel
for neurodegenerative diseases (277 genes in total) included
14 genes which were classified as disease genes when this
study was initiated, 25 putative candidate genes, modifiers,
and risk factors identified by literature research as being most
presumably implicated in ALS (e.g., by GWAS, experimental
evidence, or connected pathways; Table 1), as well as 238
genes associated with other neurodegenerative diseases (for
example genes associated with FTD, HSP and others; see
Supplementary Data, 763 kb in total). Sequencing was performed
using barcoded libraries on the SOLiD 5500xl platform according
to the manufacturer’s instructions (Fragment Library Preparation
5500 Series SOLiDTM Systems, User Guide, Applied Biosystems
by Life Technology). Approximately 2.3 million on target
reads were generated per sample and the mean coverage
on target was 184.2 sequencing reads with a mean mapping
quality of 85.3. On average 89.4% of bases were covered
by ≥10 reads/base per sample. The primary data analysis
was performed using Lifescope (versions v2.5-r0 and v2.5-
r2.5.1).
Variant Filtering
Only variants (SNVs/small indels) with a minor allele frequency
(MAF) of ≤1% in coding and flanking intronic regions (±8
base pairs) and the UTR regions were evaluated. Known disease
causing mutations which are listed in the HGMD database were
evaluated in coding and flanking intronic regions up to ±30
base pairs and up to a MAF of ≤5%. Population frequencies are
adapted from the following databases: 1000 Genomes, dbSNP,
Exome Variant Server, ExAC and an internal database. Our
quality criteria required coverage of ≥10 quality reads per
base and a novel allele frequency (NAF) of ≥0.3. Detected
variants were assessed based on their MAF, current literature and
widely used Online databases [e.g., OMIM (McKusick-Nathans
Institute of Genetic Medicine, Johns Hopkins University,
Baltimore, MD, USA), HGMD (Stenson et al., 2014), Uniprot
(UniProt Consortium, 2015), locus or disease specific databases]
and prediction tools [MutationTaster (Schwarz et al., 2014),
PolyPhen2 (Adzhubei et al., 2010), SIFT (Choi et al., 2012),
NetGene2 Server (Brunak et al., 1991) and Splice Site Prediction
by Neural Network (Reese et al., 1997)].
Comparison of Observed Frequencies
We compared the observed frequencies of affected genes in ALS
cohorts from the US (Couthouis et al., 2014), Ireland (Kenna
et al., 2013), Italy (Chiò et al., 2012) and Great Britain (Morgan
et al., 2015) with detected frequencies in our cohort.
Generation of a Protein–Protein
Interaction Network
To visually link candidate genes and possible modifiers to ALS,
and to put them in relation to each another and to confirmed
ALS genes, we created a protein–protein interaction network
containing 21 disease genes and 13 candidate genes, possible
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TABLE 1 | Genes analyzed in this study.
Gene Transcript Genetic subtype
SOD1 NM_000454.4 ALS1
ALS2 NM_020919.3 ALS2
SETX NM_015046.5 ALS4
SPG11 NM_025137.3 ALS5
FUS NM_004960.3 ALS6
VAPB NM_004738.4 ALS8
ANG NM_001145.4 ALS9
TARDBP NM_007375.3 ALS10
FIG4 NM_014845.5 ALS11
OPTN NM_021980.4 ALS12
ATXN2 NM_002973.3 ALS13
VCP NM_007126.3 ALS14
CHMP2B NM_014043.3 ALS17
C9orf72 NM_018325.3 FTDALS1
APEX1 NM_001641.3
ATXN1 NM_000332.2
CCS NM_005125.1
DAO NM_001917.4
DCTN1 NM_004082.4
DPP6 NM_001936.4
FGGY NM_001113411.1
GLE1 NM_001003722.1
GRN NM_002087.2
HEXA NM_000520.4
HFE NM_000410.3
ITPR2 NM_002223.2
KIFAP3 NM_014970.3
LIF NM_002309.4
NAIP NM_004536.2
NEFH NM_021076.3
PON1 NM_000446.5
PON2 NM_000305.2
PON3 NM_000940.2
RNF19A NM_183419.3
SLC1A2 NM_004171.3
SPAST NM_014946.3
UNC13A NM_001080421.2
VEGFA NM_001025366.2
VPS54 NM_001005739.1
The top 14 genes were classified as disease genes when this study was initiated;
a further 25 candidate genes, modifiers and risk factors were also included. Gene
names are HGNC symbols, transcripts are identified by RefSeq accessions.
risk factors, and modifiers covered by our sequencing panel
(Figure 2). The protein-protein interaction network was created
using the STRING database v102 by searching for multiple
proteins: ALS2, ANG, ATXN1, ATXN2, C9orf72, CHCHD10,
CHMP2B, DPP6, ERBB4, FGGY, FIG4, FUS, GBE1, GLE1,
GRN, HNRNPA1, ITPR2, KIFAP3, MATR3, NEFH, OPTN,
PFN1, PON3, SETX, SIGMAR1, SLC2A1, SOD1, SPG11, SPG7,
TARDBP, UBQLN2, UNC13A, VAPB, VCP. Standard settings
2http://string-db.org/
were used, network edges set to show confidence, and structural
previews inside network bubbles were disabled.
RESULTS
Identification of Variants in ALS
Associated Genes
By analyzing 39 ALS associated genes (Table 1), we were able
to detect 79 rare variants (European–American MAF ≤ 1%
in dbSNP, EVS or ExAC) in 27 genes which passed defined
filter criteria (see Variant Filtering) and manual assessment in
the Integrated Genome Viewer (IGV, v2.1.28 rev release 175,
Robinson et al., 2011; see Table 2). Of these, 34 variants have
been published previously whereas 45 have not been described
before and therefore are considered as being novel. Excluding
synonymous substitutions, we identified 54 rare variants in 23
male and 25 female patients (48 patients representing 60% of
our cohort). We found that 20 patients of whom 95% (19 out
of 20 patients) are considered as sporadic cases carry variants
in 14 known disease genes. Additionally we identified variants
in candidate genes, modifiers or risk factors in 28 patients (see
Figure 1).
Pathogenic repeat expansions in the C9orf72 gene were
identified in five (6.25%) sporadic patients (mean age of onset:
67.6 years, range 49–76 years). Two of these patients carried
additional variants in FIG4 and UNC13A (pat #10), and ITPR2
(pat #373), respectively (see Table 3). Furthermore, we identified
four patients carrying intermediate length repeat expansions
(mean age of onset: 57 years, range 40–68 years). Of these, two
individuals carried additional missense and splice variants in
ALS2 and UNC13A (pat #26), and SPG11 (pat #729) respectively
(see Table 2). Given the size of this sample, the remarkable
difference in mean age of onset between the patients with
intermediate length expansions and carriers of pathogenic repeat
expansions is not statistically significant (p = 0.11, Wilcoxon–
Mann–Whitney test).
By focusing on candidate genes, modifiers, and risk factors,
one interesting finding is the identification of four missense
variants in the GRN gene (see Table 2). Of these variants, three
have already been described as being probably benign in FTD
cases (p.T182M), of unknown clinical relevance in FTD and
progressive non-fluent aphasia (p.A324T), or as being potentially
pathogenic in FTD spectrum disease (p.V77I), respectively
(Guerreiro et al., 2008; Pickering-Brown et al., 2008; Yu et al.,
2010). Besides this, we detected seven missense variants in the
ITPR2 gene which was linked to ALS by several GWASs in the
past (van Es et al., 2007), eight variants in FGGY, and three
variants in UNC13A, as well as variants in ATXN1, DPP6, GLE1,
KIFAP3, NEFH, PON3 and SLC1A2 (see Table 2).
Co-occurrence of Variants in ALS
Associated Genes
Earlier studies supported a complex genetic basis for ALS, which
is also supported by protein–protein interactions between known
ALS-associated genes, candidate genes, risk factors, and possible
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FIGURE 1 | Detection and filtering of variants.
modifiers included in our gene panel (Figure 2). In our example,
each of the proteins interacts in the context of key proteins
for motor neuron degeneration (except CHCHD10 and PON3),
pointing toward possible modifying effects of certain variants.
We searched our cohort for patients who carry multiple
variants in ALS-associated genes and could identify 15
individuals carrying at least two variants (18.8%, synonymous
variants excluded) in ALS-associated genes (Table 4). For
example, missense variants in the ITPR2 gene were found in
co-occurrence with clearly or potentially pathogenic variants
in seven (8.75%) individuals. Four of these variants were also
detected in an ALS cohort screening by Kenna et al. (2013).
In our cohort the mean age of onset in patients who carried
a variant in the ITPR2 gene in co-occurrence was 64.0 years
compared to 66.6 years in patients carrying any other variants
in co-occurrence (differences are not statistically significant,
Wilcoxon–Mann–Whitney test). We detected two additional
synonymous variants in ITPR2 but according to current
knowledge we cannot assess their actual impact on the ITPR2
protein. Four of the 15 patients carried an expanded (Pat #10 and
Pat #373) or intermediate (Pat #26 and Pat #729) C9orf72 repeat
expansion in co-occurrence.
The mean age of onset in patients where no variant could be
detected was 57.8 years, patients who carried one variant showed
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TABLE 3 | Carriers of pathogenic and intermediate C9orf72 repeat expansions.
Pat-ID Gender Subtype AAO (years) C9orf72 n repeats Additional variants
#2 m sALS 49 Positive 30
#10 m sALS 71 Positive 35 FIG4 c.1940A > G; p.Y647C (het.); UNC13A c.3080C > T; p.P1027L (het.)
#24 m sALS 70 Positive 31
#373 f sALS 72 Positive 34 ITPR2 c.3485T > G; p.V1162G (het.)
#673 f sALS 76 Positive n.a.
#6 m sALS 68 Intermediate 26
#25 f flail leg syndrome 54 Intermediate 27
#26 m sPLS 66 Intermediate 27 UNC13A c.182C > T; p.T61M (het.); ALS2 c.1816-8C > T; p.?
#729 m sALS 40 Intermediate 27 SPG11 c.5381T > C; p.L1794P (het.)
a mean age of onset of 61.3 years and patients carrying two or
more variants had a mean age of disease onset of 65.0 years. In
comparison, the overall mean age of disease onset in our cohort
was 60.1 years. However, these differences in age of onset are not
statistically significant (Kruskal–Wallis Rank Sum Test).
Variants in Other NDD Genes
To match the hypothesis of common pathways in different
neurodegenerative diseases (NDDs) and to link ALS to other
entities of the NDD spectrum, we additionally searched for
potentially pathogenic or disease causing variants in 238
genes which are associated with possible differential diagnoses
or overlapping phenotypes that are included in our NDD
gene panel. We identified 12 patients who carried potentially
pathogenic variants in genes that are linked to other entities
(Table 5).
In patient #38, we detected two heterozygous variants in the
GBE1 gene (p.S378R and p.P40T, see Table 5). Mutations in GBE1
can cause autosomal recessively inherited adult Polyglucosan
body disease (APBD) which is characterized by upper motor
neuron signs similar to ALS, early neurogenic bladder, cognitive
impairment and decreased or absent activity of the glycogen
branching enzyme (Klein, 2013). APBD is one of the conditions
that should be considered when establishing the diagnosis of
ALS. Unfortunately, we could not investigate whether both
variants occur in the compound-heterozygous state in our patient
because samples for segregation analysis could not be obtained.
Long-range PCR with mutation-specific primers was impossible
due to the large distance of more then 170 kb between the
variants.
Another interesting finding is the identification of
heterozygous variants in the SPG7 gene in four sporadic
patients (see Table 5). Mutations in SPG7 can cause autosomal
recessively inherited spastic paraplegia type 7, but there are
also some published cases of obviously autosomal dominant
inheritance (e.g., Sánchez-Ferrero et al., 2013). The disease is
mainly characterized by spasticity and weakness of the lower
limbs. Additional neurologic symptoms might appear in more
complex phenotypes. In our cohort, we identified the truncating
mutation p.R213* and the missense mutations p.I743T and
p.G349S which are both described as acting disadvantageous
on SPG7 protein function (Brugman et al., 2008; Bonn et al.,
2010). None of the four patients had further relevant variants
in ALS associated genes (only one patient carries an additional
missense variant of unknown clinical relevance in the FGGY
gene).
We also identified a high number of variants in the NOTCH3,
SYNE1, and VPS13A genes as expected in genes of this size. For
SYNE1, as mainly loss-of-function mutations are considered as
being pathogenic in motor neuron disease (Gros-Louis et al.,
2007; Izumi et al., 2013; Noreau et al., 2013). Similarly, only
variants which result in a loss or gain of one cysteine residue
within epidermal growth factor (EGF)-like repeat domains
(Dichgans et al., 2001) are considered pathogenic in NOTCH3,
and for VPS13A mostly loss-of-function variants are considered
as pathogenic (Tomiyasu et al., 2011). Thus we assume that
detected variants in our cohort represent rare polymorphisms.
We identified variants in further genes that are included in our
gene panel (see Table 5) but are unlikely to be implicated in our
patients’ phenotypes.
By comparing the number of patients identified to carry
potentially pathogenic variants in ALS related genes in our
cohort with previously published cohort studies, we show that
the frequency of affected genes may vary in different populations
(Table 6). For example, in the VAPB gene we detected variants in
5% of German patients (four cases) whereas in other populations
no variants in VAPB were identified at all. Striking differences
in frequencies across populations can also be observed for FIG4,
FGGY, GRN, ITPR2, and UNC13A. The studies used vastly
different strategies for sequencing and variant evaluation and
analyzed different gene sets [from 6 genes, partially hotspots
only sequenced by Sanger in Chiò et al. (2012) to 169 genes
sequenced by NGS in Couthouis et al. (2014)]. Thus we consider
this comparison solely to hint toward possible differences in
gene frequencies among populations as a consequence of founder
effects.
DISCUSSION
By using next-generation sequencing we analyzed 39 ALS-
associated genes in a German cohort of both familial and sporadic
ALS patients. In total, we detected 54 rare variants in approved
disease genes and possible candidate genes, risk factors, and
modifiers (synonymous variants excluded) in 48 patients which
represents 60% of our total cohort.
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FIGURE 2 | Protein–protein-interaction network including 21 known ALS genes as well as 13 candidate genes, risk factors and possible modifiers
included in our ALS gene panel (created with STRING10, Jensen et al., 2009). UBC, Ubiquitin C.
We identified pathogenic or potentially pathogenic variants
in 14 analyzed disease genes in 20 patients of whom 19 patients
(95%) are affected by sporadic ALS. This finding is unexpected,
as it demonstrates that a genetic background can actually be
found in a major proportion of seemingly sporadic cases (25%;
19 of 74 patients with sALS). We also would have expected
to find more variants in familial cases. Although guidelines
and recommendations on how to evaluate unknown variants
are published (see for example Richards et al., 2015), the
assessment of the actual pathogenicity of detected unknown
variants with regard to the patients’ phenotypes remains
challenging and clear evidence on how a certain variant impairs
the phenotype can only be achieved by extensive functional
studies.
By focusing on possible candidate genes, risk factors, and
modifiers, an interesting finding is the detection of heterozygous
missense variants in the GRN gene in four patients affected by
pure ALS (see Table 2). Three of the identified variants (p.V77I,
p.V121M and p.A324T) are classified as being potentially
pathogenic. Loss-of-function mutations in GRN are considered
causative for frontotemporal lobar degeneration with ubiquitin-
positive inclusions (Mackenzie et al., 2006). Recent evidence
though suggests that missense mutations in GRN are also
linked to the pathogenesis of ALS, especially as ALS and
frontotemporal dysfunction are considered to represent a
continuum of overlapping phenotypes, and a large proportion of
ALS patients additionally experience frontotemporal dysfunction
and vice versa (Sleegers et al., 2008; Cannon et al., 2013). Based
on our findings, we recommend that GRN gene analysis should
be included in routine molecular diagnostic settings and should
also be considered in cases of pure ALS without frontotemporal
involvement. Further, we detected seven missense variants in
the ITPR2 gene. Although Fernández-Santiago et al. (2011) as
well as Chen et al. (2012) could not confirm an association
of variants in ITPR2 with ALS in a German and a Chinese
cohort by SNP genotyping, we speculate that variation in
the ITPR2 gene could act as a modulating factor in ALS.
A modulating effect might also exist for variants in FGGY
(eight variants), GRN (four variants) and UNC13A (three
variants).
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These findings reflect the overall challenges in assessing
the relevance of rare variants with respect to the phenotype
as functional studies investigating the actual effect of these
variants are largely missing. However, by the implementation
of NGS in clinical genetics, we are now faced with increasing
numbers of genes published as being possibly implicated in
the pathogenesis of ALS. Such candidate genes gain further
support from protein-protein interaction data. As rare variants
TABLE 4 | Co-occurrence of variants in ALS associated genes.
Pat-ID Gender Subtype AAO (years) Gene cDNA Protein MAF_EA (%) dbSNP
#10 m sALS 71 C9orf72 Pathogenic repeat expansion
FIG4 c.1940A > G p.Y647C 0.02 rs150301327
UNC13A c.3080C > T p.P1027L 0.65 rs200328448
#22 f sALS 67 ATXN2 c.2088C > T p.(=) - -
ITPR2 c.2831C > T p.P944L 0.01 rs377598368
VAPB c.390T > G p.D130E 0.1 rs146459055
#26 m PLS 66 C9orf72 Intermediate repeat expansion
ALS2 c.1816-8C > T p.? 0.38 rs185911369
UNC13A c.4560C > T p.(=) 0.07 rs141334897
UNC13A c.4143G > A p.(=) - -
UNC13A c.182C > T p.T61M 0.2 rs140141294
#422 f sALS 61 ALS2 c.4119A > G p.I1373M 0.49 rs61757691
FUS c.-37C > T p.? - -
ITPR2 c.1834G > A p.A612T 0.01 rs199523133
NEFH c.2646C > T p.(=) - -
#524 f sALS 60 ALS2 c.1816-8C > T p.? 0.38 rs185911369
SLC1A2 c.236C > G p.A79G 0.01 rs377633002
#677 f sALS 72 ITPR2 c.8002G > A p.A2668T 0.29 rs61757116
VAPB c.479_481delCTT p.S160del 0.45 rs566283411
#741 f sALS 64 FUS c.∗41G > A p.? 0.58 rs80301724
ITPR2 c.3635C > T p.A1212V - rs368911384
TARDBP c.931A > G p.M311V - rs80356725
#29 f sALS 73 ITPR2 c.1447G > A p.V483I - -
SETX c.7358A > G p.K2453R - -
#28 f ALS 67 FGGY c.979A > C p.N327H 0.1 rs34026954
GRN c.361G > A p.V121M - -
#34 f ALS-FTD 54 ATXN1 c.1117C > T p.R373C - -
ATXN2 c.2049A > T p.L683F - -
#36 m flail arm 39 GRN c.970G > A p.A324T 0.14 rs63750541
ITPR2 c.3539G > A p.R1180Q 0.76 rs35862420
#38 f ALS-FTD 70 ATXN1 c.511C > A p.R171S - -
FGGY c.979A > C p.N327H 0.1 rs34026954
#47 m sALS 78 APEX1 c.∗2A > T p.? 0.66 rs17112002
PON3 c.217G > T p.G73C - -
#373 f sALS 72 C9orf72 Pathogenic repeat expansion
ITPR2 c.3485T > G p.V1162G 0.15 rs61757114
#729 m sALS 40 C9orf72 Intermediate repeat expansion
PON1 c.603G > A p.(=) 0.12 rs148452713
SPG11 c.5381T > C p.L1794P 0.01 rs201689565
#3 m fALS 41 UNC13A c.771C > G p.(=) 0.85 rs146739681
VAPB c.166C > T p.P56S - rs74315431
#16 m sALS 67 GRN c.545C > T p.T182M 0.03 rs63750479
ITPR2 c.4962G > A p.(=) 0.36 rs191789657
NEFH c.2061A > G p.(=) - -
(Continued)
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TABLE 4 | Continued
Pat-ID Gender Subtype AAO (years) Gene cDNA Protein MAF_EA (%) dbSNP
#24 m sALS 70 C9orf72 pathogenic repeat expansion
DPP6 c.693T > C p.(=) - -
ITPR2 c.5569C > T p.(=) 0.17 rs191281974
#749 m sALS 46 GRN c.229G > A p.V77I 0.01 rs148531161
HEXA c.744C > T p.(=) - -
#33 m sALS 63 FGGY c.1221+2T > C p.? 0.45 rs41287704
SETX c.6675C > T p.(=) 0.01 rs200382898
#46 f ALS-FTD 75 SLC1A2 c.846C > A p.(=) - -
SOD1 c.-8A > C p.? - -
#52 m sALS 45 KIFAP3 c.1301T > G p.F434C 0.23 rs116755924
SLC1A2 c.450G > A p.(=) - -
in ALS associated genes according to current knowledge
rather represent modifiers with effect on risk of developing
the disease, age of onset, severity, or progression rate than
disease causing mutations, further effort has to be made to
understand how these modulating effects become evident in
ALS. Investigating such modulating effects might lead to the
identification of pathways that are not yet linked to ALS,
enhancing our knowledge of ALS pathogenesis and higher-level
neurodegenerative processes.
By performing repeat length analysis we identified five
sporadic patients (6.25%) carrying pathogenic repeat expansions
in the C9orf72 gene. This is in line with Majounie et al.
(2012) who reported on 5.2% of C9orf72 repeat expansion
carriers amongst German ALS patients. In two carriers of a
pathogenic repeat expansion, we detected additional variants
in ALS-associated genes. Although van Blitterswijk et al.
(2012) suggested that additional genetic factors contribute to
ALS pathogenesis in some carriers of a pathogenic C9orf72
repeat expansion, we cannot assess the impact of additional
variants on the patients’ phenotypes in our cohort study. We
identified four further patients carrying intermediate length
repeat expansions. According to recent literature, these might
be pathogenic in ALS as patients carrying 20–29 repeats are
phenotypically similar to those with more than 30 repeats
(Byrne et al., 2014). However, as intermediate length repeats
have been detected in both patients and healthy controls,
their actual pathogenicity still remains unclear (Rohrer et al.,
2015). Of the four individuals with intermediate length repeat
expansions, two patients carried additional variants in disease
related genes. In our cohort, patients with intermediate length
repeats had an earlier age of onset than carriers of a pathogenic
repeat expansion (averages of 57.0 and 67.6 years, respectively).
This counter-intuitive result leads us to speculate that age of
onset was not primarily influenced by the length of repeat
expansions but possibly by other factors such as additional
variants in other genes. However, we cannot draw a firm
conclusion due to our limited cohort size. Surprisingly, we did
not detect pathogenic repeat expansions in any of the familial
cases, although this might also be because of the small sample
size.
To evaluate the hypothesis that ALS might be of complex
genetic origin, we searched our cohort for patients carrying
more than one potentially disease-causing variant. We found
that 15 patients (18.8% of our cohort, synonymous variants
excluded) carry two or more variants in ALS-associated genes
and that four of these 15 patients additionally carry an
expanded or intermediate C9orf72 repeat expansion. According
to current findings, a complex model of inheritance is used to
explain phenomena like reduced penetrance or even intrafamilial
phenotypic variability. A hypothesis by Cady et al. (2015) for
example implies that disease onset is influenced by the burden of
rare variants in ALS-associated genes. The authors reported that
3.8% of 391 study participants harbored two or more variants in
17 analyzed disease genes and that these individuals had disease
onset 10 years earlier than patients carrying only one variant.
The considerable difference in percentage of patients carrying
two or more variants (3.8% in Cady et al., 2015 vs. 18.8% in
this study) might be explained by the fact that we included not
only variants in approved disease genes but also in candidate
genes, modifiers, and risk factors. In contrast, Cirulli et al. (2015)
did not report an effect of the number of variants on the age of
onset in their cohort of 2869 ALS patients and 6405 controls,
but they do not draw a strong conclusion as they did not test
for pathogenic C9orf72 repeat expansions. In our data, we do see
a later age of onset in patients carrying two or more variants.
However, due to our smaller sample size, we cannot make
statistically significant observations on a possible correlation
and we cannot exclude that co-occurrence of multiple variants
might have a disadvantageous effect on disease onset, severity,
disease duration, or site of onset by affecting disease causing
variants. As an example, the identification of ITPR2 variants in
co-occurrence in seven patients might hint at a possible negative
effect of additional variants in the ITPR2 gene. Further studies
should include both next-generation sequencing and tests for
pathogenic repeat expansion in a large cohort to resolve this open
question.
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To genetically and mechanistically link ALS to other
pathologies of the NDD spectrum, we searched our cohort for
potentially pathogenic variants in 238 genes that are associated
with overlapping phenotypes and are covered by our diagnostic
panel.
We identified potentially pathogenic variants in
neurodegeneration-related genes in 12 patients. Although
compound-heterozygosity for the detected variants in GBE1
in pat #38 is not proven, we speculate that both variants
might be at least concurrently causative, especially as the
patient revealed UMN-dominant ALS, cognitive impairment,
and progressive non-fluent aphasia (PNFA) upon his last
clinical examination in 2012. GBE1 is a glycogen branching
enzyme which is involved in glycogen synthesis. According
to Ngo and Steyn (2015), there is a link between the selective
degeneration of neurons in ALS and metabolic alterations:
Deficits caused by decreased glucose metabolism may trigger
hyperexcitability and subsequent selective degeneration of
upper and lower motor neurons. Although the underlying
mechanisms are still unclear, Wang et al. (2015) could show
that the FUS protein (juvenile ALS) interacts to a great
extent with mitochondrial enzymes and proteins involved in
glucose metabolism. With regard to these presumptions, we
speculate that pathogenic variants in GBE1 might be causative
TABLE 6 | Percentage of patients carrying potentially pathogenic variants in ALS associated genes (missense, splicing, small Indels only) (American:
Couthouis et al., 2014; Irish: Kenna et al., 2013; Italian: Chiò et al., 2012; British: Morgan et al., 2015).
Gene Our cohort (%) n = 80 American (%) n = 242 Irish (%) n = 444 Italian (%) n = 475 British (%) n = 95
SOD1 1.25 1.65 0 2.1 2.11
ALS2 5 1.24 1.35 - 5.26
SETX 2.5 2.07 2.25 – –
SPG11 3.75 4.13 1.58 – 17.89
FUS 2.5 0.41 0.45 0.21 1.05
VAPB 5 0 0 – –
ANG 0 0.41 0 0 –
TARDBP 1.25 – 0.45 1.47 2.11
FIG4 2.5 0.83 0 – –
OPTN 0 0 0.23 0.21 2.11
ATXN2 1.25 1.22 0 – –
VCP 1.25 0 0.23 – –
CHMP2B 0 0 0.45 – –
C9orf72-Repeat 6.25 1.65 8.78 6.74 –
APEX1 1.25 – – – –
ATXN1 2.5 – – – –
CCS 0 – – – –
DAO 0 – – – –
DCTN1 0 2.07 0.45 – –
DPP6 1.25 1.65 0.23 – –
FGGY 10 0.41 0.23 – –
GLE1 1.25 – – – –
GRN 5 0.41 0 – –
HEXA 0 – – – –
HFE 0 1.65 0.23 – –
ITPR2 8.75 1.24 0.23 – –
KIFAP3 2.5 – – – –
LIF 0 – – – –
NAIP 0 – – – –
NEFH 1.25 0.41 0 – –
PON1 0 0 0 – 1.05
PON2 0 0 0.23 – 1.05
PON3 1.25 0 0 – –
RNF19A 0 – – – –
SLC1A2 1.25 – – – –
SPAST 0 – – – –
UNC13A 3.75 1.24 0.23 – –
VEGFA 0 – – – 1.05
VPS54 0 – – – –
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for ALS or motor neuron degeneration, and that metabolic
processes and involved genes must be taken into account in ALS
genetics.
We detected known heterozygous variants in SPG7
(paraplegin) in four patients. Recent evidence suggests that
mutations in SPG7 might be relevant in PLS as Mitsumoto
et al. (2015) reported on the identification of a pathogenic
heterozygous variant in SPG7 in a patient affected by PLS.
Paraplegin is part of the metalloprotease AAA complex, an
ATP-dependent proteolytic complex located on the inner
mitochondrial membranes, and functions in controlling
protein quality and ribosomal assembly. Ferreirinha et al.
(2004) showed that paraplegin-deficient mice develop axonal
swellings as a consequence of accumulation of mitochondria
and neurofilaments in the spinal cord which precedes axonal
degeneration by impaired anterograde axonal transport.
Although further studies are needed to assess the functional
role of SPG7 in human motor neurons, these findings hint
at an important role of SPG7 in motor neuron survival and
support our hypothesis, that paraplegin is implicated in the
pathogenesis of ALS and those pathogenic mutations in
SPG7 must be taken into account regarding genetic testing in
ALS.
In summary, our results support recent observations whereby
a genetic background is implicated in the sporadic form of ALS to
a higher extent than assumed so far, and strengthen the upcoming
hypothesis of ALS being a distinct manifestation of higher-level
neurodegenerative processes rather than representing a discrete
entity. Further, our results contribute to current discussions
on a possible pathogenicity of intermediate repeat expansion
in the C9orf72 gene, especially in the interplay with additional
variants in other ALS associated genes. In contrast to previously
published studies, we could not prove an earlier age of disease
onset in patients carrying multiple variants but speculate that
variants in the ITPR2 gene might act as a modulating factor in
ALS. Additionally, our results lead us to assume that variants
in GRN and SPG7 might be implicated in the pathogenesis
of ALS which is in line with the aforementioned hypothesis
of common neurodegenerative processes leading to distinct
phenotypes. Surprisingly, we did not detect clearly pathogenic
variants in SOD1 in our cohort, even though this gene is
supposed to have a high impact on disease, encouraging us
to launch a debate on the actual significance of SOD1 in
Germany.
CONCLUSION
We investigated 39 ALS-associated genes in a German cohort
of 80 familial and sporadic ALS patients utilizing next-
generation sequencing. We identified 22 variants in disease-
causing genes in 20 patients and additionally 32 variants in
candidate genes, risk factors, and modifiers in 28 patients.
Thus we detected variants in ALS-associated genes in 60%
of our study participants, of whom the vast majority are
sporadic cases. Surprisingly, pathogenic repeat expansions in
C9orf72 and potentially pathogenic variants in SOD1 were
both detected at lower frequencies than expected. Instead we
identified potentially pathogenic variants in the GRN gene in
four patients, indicating that the impact of GRN mutations
is not limited to ALS-FTD and might account for pure ALS,
too.
Furthermore, our cohort enabled us to evaluate the hypotheses
that ALS is of complex genetic origin. According to this
hypothesis, numerous variants have some degree of influence on
the clinical phenotype caused by the pathogenic mutation. We
did in fact identify patients carrying variants in more than one
ALS-associated gene. In contrast to other studies, however, our
results do not show that patients with multiple variants have an
earlier age of onset.
As ALS should be seen in the context of wider
neurodegenerative disorders, we investigated our cohort for
potentially pathogenic variants in 238 neurodegeneration
related genes. The most interesting findings are the
identification of two variants in the GBE1 gene that
might be causative in a patient with UMN-dominant
ALS and the detection of heterozygous variants in SPG7
in four ALS patients. These findings would benefit from
extensive high-throughput sequencing in large patient and
control cohorts of different ethnic background in order
to more accurately assess the overall variability in ALS-
associated genes and to better evaluate their impact on the
disease.
Our results support the notion that next-generation
sequencing could help uncover the genetic heterogeneous
basis of ALS and thus argue for the broader application of NGS
techniques in routine diagnostic settings. Therefore, our results
are of immediate relevance for clinical genetics as we recommend
that genetic testing in German patients should be offered not
only to those with familial ALS but also to those with apparently
sporadic ALS. We propose a two-stage strategy starting with a
C9orf72 repeat analysis, followed by comprehensive gene panel
sequencing if C9orf72 negative. To meet the high number of
possible differential diagnoses that mimic ALS, genes causing
FTD, HSP, spinal muscular atrophy (SMA) and other entities
that impair motor neuron function should be included. Whereas
Sanger sequencing focused on a few commonly affected genes
such as SOD1, panel sequencing offers the opportunity to cover
all disease-associated genes in only one approach and thus
reveals the genetic heterogeneity of ALS and increases detection
rates. Additionally, panel sequencing allows for the detection
of multiple variants acting on the individual phenotype which
might enable statements for example on disease progression
or severity. We hope that our results will contribute to deeper
knowledge which will allow the identification of new therapeutic
targets for example by interfering with distinct pathways or
personalized therapeutic approaches in the future.
It was our aim to broaden the genetic landscape of ALS.
We detected previously identified ALS-causing mutations, novel
variants within recognized disease-causing genes and candidate
genes, in addition to modifiers and risk factors. Assessing
the impact of newly detected variants and their potential
contribution to the ALS phenotype requires further investigation
in order to determine their functional relevance. For several
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patients who gave their informed consent, we collected fibroblasts
to provide the basis for the necessary functional work up.
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